Close
Patheon
Multiplexing: Managing Risk with Proven, Single-Use Solutions
Biologics
Author: Marc Goemans
Monday, August 22, 2016

When pharmaceutical companies introduce a new drug to market, they invest enormous amounts of capital, and assume equally enormous amounts of risk. As it usually takes three-to-four years to prepare manufacturing capacity for the large scale production of a new product, the decision as to how much volume a company will need often must be made before Phase III trials are completed. At that point, it is difficult for developers to forecast demand. Therefore, deciding how much manufacturing capacity they will need is problematic, to say the least. Underestimating or overestimating demand can have a devastating impact on the bottom line.

 

Please complete the short form below to download this whitepaper.

Looking for Solutions?

We can help.